Medicure (MCUJF) Return on Capital Employed (2009 - 2026)
Medicure's (MCUJF) quarterly Return on Capital Employed came in at 13.71% in Q1 2026, up 3074.0% year-on-year from 0.43% in Q1 2025, and up 645.07% quarter-over-quarter from 2.52% in Q4 2025.
Medicure (MCUJF) Return on Capital Employed (2009 - 2026) Analysis & Trends
Medicure's Return on Capital Employed history runs 18 years deep, the most recent figure standing at 13.71% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 3074.0% year-over-year to 13.71% in Q1 2026; TTM through Mar 2026 was 13.71%, a 3074.0% increase from a year earlier, with the FY2025 full-year figure at 43.04%, down 2980.0% from the prior year.
- Return on Capital Employed rose to 13.71% in Q1 2026 per MCUJF's latest filing, from 2.52% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 51.52% in Q1 2023 and bottomed at 17.03% in Q1 2025.
- The 5-year median for Return on Capital Employed is 2.52% (2025), against an average of 4.91%.
- Across the five-year window, Return on Capital Employed jumped 4731 bps in 2023 and plunged 4732 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 39.06% in 2022, then retreated by 25 bps to 29.34% in 2023, then sank by 145 bps to 13.25% in 2024, then surged by 81 bps to 2.52% in 2025, then soared by 645 bps to 13.71% in 2026.
- Per Business Quant, the three latest MCUJF Return on Capital Employed figures stand at 13.71% (Q1 2026), 2.52% (Q4 2025), and 4.99% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Medicure | 8.77 Mn | 7.64 Mn | 2.57 Mn | 13.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.71% |
| Dec 31, 2025 | -2.52% |
| Sep 30, 2025 | -4.99% |
| Jun 30, 2025 | -15.73% |
| Mar 31, 2025 | -17.03% |
| Dec 31, 2024 | -13.25% |
| Sep 30, 2024 | -9.01% |
| Jun 30, 2024 | -2.92% |
| Mar 31, 2024 | 4.20% |
| Dec 31, 2023 | 29.34% |
| Mar 31, 2023 | 51.52% |
| Dec 31, 2022 | 39.06% |
| Sep 30, 2022 | 2.66% |
| Jun 30, 2022 | -5.67% |
| Mar 31, 2022 | 4.21% |
| Sep 30, 2021 | -29.00% |
| Jun 30, 2021 | -20.46% |
| Mar 31, 2021 | -26.21% |
| Dec 31, 2020 | -35.79% |
| Sep 30, 2020 | -28.39% |